Skip to main content

12-20-2022 | Dapagliflozin | News


Dapagliflozin on way to EC approval for all heart failure

Author: Eleanor McDermid


medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended extension of the dapagliflozin license to encompass all heart failure irrespective of the ejection fraction.

The sodium-glucose cotransporter 2 inhibitor was previously approved for people with symptomatic heart failure and a reduced ejection fraction, but the recent DELIVER trial demonstrated its efficacy in people with a preserved ejection fraction.

Dapagliflozin is also approved for treatment of type 2 diabetes in adults and children older than 10 years, and for treatment of chronic kidney disease.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video